Science Explorer Back to mapMap
Discussion
Company · Chengdu · China

Clover Biopharmaceuticals (China)

cloverbiopharma.comROR OpenAlex
Research works
19
▲ 113% vs 2018-21
Citations
244
12.6 per fractional work
Top-10% rate
7.7%
all institutions 10.0%
Open access
52%
world 40%
International
25%
world 18%
Clover Biopharmaceuticals (China)

Not ranked overall: Clover Biopharmaceuticals (China) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Clover Biopharmaceuticals (China) work in?

In all years, 46% of research at Clover Biopharmaceuticals (China) is in Health Sciences, 35% in Life Sciences. Its largest fields are Medicine (46%), Biochemistry, Genetics and Molecular Biology (18%), Chemistry (9%). It does 1.6× the world's share of Life Sciences.

Health Sciences: 9 fractional works · 46.1% of its workMedicine: 9 fractional works · 46.1% of its workOncology: 2 fractional works · 9.5% of its workRadiology, Nuclear Medicine and Imaging: 2 fractional works · 8.2% of its workInfectious Diseases: 1 fractional works · 7.6% of its workNeurology: 1 fractional works · 4.1% of its workRheumatology: 1 fractional works · 2.6% of its workEpidemiology: 0 fractional works · 2.2% of its workPulmonary and Respiratory Medicine: 0 fractional works · 1.8% of its workOphthalmology: 0 fractional works · 1.5% of its workGenetics: 0 fractional works · 1.4% of its workSurgery: 0 fractional works · 1.4% of its workPharmacology: 0 fractional works · 1.2% of its workRehabilitation: 0 fractional works · 0.9% of its workHematology: 0 fractional works · 0.6% of its workComplementary and alternative medicine: 0 fractional works · 0.6% of its workPublic Health, Environmental and Occupational Health: 0 fractional works · 0.6% of its workDermatology: 0 fractional works · 0.4% of its workPhysiology: 0 fractional works · 0.4% of its workImmunology and Allergy: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.5% of its workHealth Professions: 0 fractional works · 0.1% of its workLife Sciences: 7 fractional works · 34.6% of its workBiochemistry, Genetics and Molecular Biology: 4 fractional works · 18.3% of its workMolecular Biology: 2 fractional works · 12.5% of its workBiotechnology: 0 fractional works · 2.3% of its workPhysiology: 0 fractional works · 1.7% of its workGenetics: 0 fractional works · 1.1% of its workCancer Research: 0 fractional works · 0.6% of its workImmunology and Microbiology: 1 fractional works · 6.4% of its workImmunology: 1 fractional works · 6.4% of its workAgricultural and Biological Sciences: 1 fractional works · 5.1% of its workAnimal Science and Zoology: 0 fractional works · 2.2% of its workPlant Science: 0 fractional works · 1.5% of its workAquatic Science: 0 fractional works · 0.9% of its workFood Science: 0 fractional works · 0.6% of its workNeuroscience: 1 fractional works · 3.5% of its workNeurology: 0 fractional works · 1.7% of its workSensory Systems: 0 fractional works · 1.7% of its workSmaller subfields together: 0 fractional works · 0.1% of its workPharmacology, Toxicology and Pharmaceutics: 0 fractional works · 1.3% of its workPharmaceutical Science: 0 fractional works · 1.0% of its workPharmacology: 0 fractional works · 0.4% of its workPhysical Sciences: 4 fractional works · 18.7% of its workChemistry: 2 fractional works · 9.2% of its workOrganic Chemistry: 2 fractional works · 8.0% of its workInorganic Chemistry: 0 fractional works · 0.9% of its workAnalytical Chemistry: 0 fractional works · 0.4% of its workComputer Science: 1 fractional works · 5.2% of its workComputer Networks and Communications: 1 fractional works · 3.5% of its workHardware and Architecture: 0 fractional works · 1.7% of its workEngineering: 0 fractional works · 1.7% of its workBiomedical Engineering: 0 fractional works · 1.7% of its workMaterials Science: 0 fractional works · 1.7% of its workBiomaterials: 0 fractional works · 1.7% of its workEnvironmental Science: 0 fractional works · 0.6% of its workEcology: 0 fractional works · 0.6% of its workChemical Engineering: 0 fractional works · 0.3% of its workCatalysis: 0 fractional works · 0.3% of its workSocial Sciences: 0 fractional works · 0.6% of its workSocial Sciences: 0 fractional works · 0.6% of its workHealth: 0 fractional works · 0.6% of its workALL ITS WORKCloverBiopharmaceutica…19fractional works, all years
Life Sciences35%Physical Sciences19%Health Sciences46%Social Sciences1%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 14 fields, with their numbers
    1. Medicine946.1%
    2. Health Professions00.1%
    1. Biochemistry, Genetics and Molecular Biology418.3%
    2. Immunology and Microbiology16.4%
    3. Agricultural and Biological Sciences15.1%
    4. Neuroscience13.5%
    5. Pharmacology, Toxicology and Pharmaceutics01.3%
    1. Chemistry29.2%
    2. Computer Science15.2%
    3. Engineering01.7%
    4. Materials Science01.7%
    5. Environmental Science00.6%
    6. Chemical Engineering00.3%
    1. Social Sciences00.6%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Agricultural and Biological Sciences: 1.21× its world share, 1 worksAgricultural and Bio…Biochemistry, Genetics and Molecular Biology: 3.17× its world share, 2 worksBiochemistry, Geneti…Immunology and Microbiology: 6.27× its world share, 1 worksImmunology and Micro…Neuroscience: 3.54× its world share, 1 worksNeurosciencePharmacology, Toxicology and Pharmaceutics: 4.75× its world share, 0 worksPharmacology, Toxico…Chemical Engineering: 1.37× its world share, 0 worksChemical EngineeringChemistry: 5.79× its world share, 1 worksChemistryEngineering: 0.19× its world share, 0 worksEngineeringMaterials Science: 0.82× its world share, 0 worksMaterials ScienceHealth Professions: 0.04× its world share, 0 worksHealth ProfessionsMedicine: 2.46× its world share, 6 worksMedicineSocial Sciences: 0.08× its world share, 0 worksSocial Sciences1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 6.3×. Every wedge is a field page.

All 12 fields, with their numbers
  1. Immunology and Microbiology6.27×1 works
  2. Chemistry5.79×1 works
  3. Pharmacology, Toxicology and Pharmaceutics4.75×0 works
  4. Neuroscience3.54×1 works
  5. Biochemistry, Genetics and Molecular Biology3.17×2 works
  6. Medicine2.46×6 works
  7. Chemical Engineering1.37×0 works
  8. Agricultural and Biological Sciences1.21×1 works
  9. Materials Science0.82×0 works
  10. Engineering0.19×0 works
  11. Social Sciences0.08×0 works
  12. Health Professions0.04×0 works

Who are the top researchers at Clover Biopharmaceuticals (China)?

Ranked on the quality score, Peng Liang and Joshua G. Liang lead among researchers whose main affiliation is Clover Biopharmaceuticals (China).

  1. 1 Peng Liang China · #869,496 worldwide 2.8k citations · 121 works
  2. 2 Joshua G. Liang China · #1,194,160 worldwide 818 citations · 20 works
All ranked researchers at Clover Biopharmaceuticals (China)

What are the most cited papers from Clover Biopharmaceuticals (China)?

The most cited paper from Clover Biopharmaceuticals (China) is "Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial" (Peter Richmond, Lara Hatchuel, Min Dong et al., 2021), with 284 citations. Next come "S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates" (162) and "Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial" (113).

Most cited papers
#PaperReleasedCitations
1 Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial Peter Richmond, Lara Hatchuel, Min Dong et al. · The Lancet Open access 29 Jan 2021 284
2 S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates Joshua G. Liang et al. · Nature Communications Open access Mar 2021 162
3 Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial Lulu C Bravo et al. · The Lancet Open access 2022 113
4 Improvement of Pharmacokinetic Profile of TRAIL via Trimer-Tag Enhances its Antitumor Activity in vivo Haipeng Liu, Danmei Su, Jinlong Zhang et al. · Scientific Reports Open access 15 Aug 2017 93
5 Deep learning models for predicting RNA degradation via dual crowdsourcing Hannah K. Wayment-Steele et al. · Nature Machine Intelligence Open access 14 Dec 2022 59
All 47 most cited papers, with filters and sorting

Which research topics does Clover Biopharmaceuticals (China) publish most on?

By volume in 2022-now: PARP inhibition in cancer therapy, Phagocytosis and Immune Regulation, SARS-CoV-2 and COVID-19 Research and Monoclonal and Polyclonal Antibodies Research.

PARP inhibition in cance…1PARP inhibition in cancer therapy: 1 fractional worksPhagocytosis and Immune …1Phagocytosis and Immune Regulation: 1 fractional worksSARS-CoV-2 and COVID-19 …1SARS-CoV-2 and COVID-19 Research: 1 fractional worksMonoclonal and Polyclona…1Monoclonal and Polyclonal Antibodies Research: 1 fractional worksLong-Term Effects of COVID-19: 0 fractional worksRadiopharmaceutical Chemistry and Applications: 0 fractional worksGlycosylation and Glycop…0Glycosylation and Glycoproteins Research: 0 fractional worksClick Chemistry and Applications: 0 fractional worksPeripheral Neuropathies and Disorders: 0 fractional worksCancer Research and Treatments: 0 fractional works
OncologyImmunologyInfectious DiseasesRadiology, Nuclear Medicine and Imaging4 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 PARP inhibition in cancer therapy Oncology 1 works
  2. 2 Phagocytosis and Immune Regulation Immunology 1 works
  3. 3 SARS-CoV-2 and COVID-19 Research Infectious Diseases 1 works
  4. 4 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 1 works
  5. 5 Long-Term Effects of COVID-19 Neurology 0 works
  6. 6 Radiopharmaceutical Chemistry and Applications Radiology, Nuclear Medicine and Imaging 0 works
  7. 7 Glycosylation and Glycoproteins Research Molecular Biology 0 works
  8. 8 Click Chemistry and Applications Organic Chemistry 0 works
  9. 9 Peripheral Neuropathies and Disorders Neurology 0 works
  10. 10 Cancer Research and Treatments Biotechnology 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available52.5%not open47.5%

World: 40% of research is openly available.

with international co-authors25.3%domestic only74.7%

World: 18% is written across borders.

How has Clover Biopharmaceuticals (China)'s research output changed?

Output in 2022-2025 was 113% higher than in 2018-2021.

still counting20052010201520202025
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Clover Biopharmaceuticals (China) as a percentage of every work published that year, 0.000012% in 2024.

still counting0.000025%0.000050%0.000075%Clover Biopharmaceuticals (China)0.000033% in 202520102020

Fractional works of Clover Biopharmaceuticals (China) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Chengdu

All research institutions in Chengdu

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Clover Biopharmaceuticals (China). Posts are plain text and can be reported.